Other

Novo Nordisk to buy RNA technology firm

Denmark's Novo Nordisk, the world's leading insulin maker, said Thursday it will buy US-based Dicerna Pharmaceuticals, a developer of RNA interference technology which targets genes that cause disease.

Medical research

Study finds cosmetic products contain endocrine disruptors

Researchers from the University of Granada and the San Cecilio de Granada Teaching Hospital confirm that endocrine disruptors—chemical substances that may mimic or block the action of hormones—are present in some cosmetic ...

page 5 from 21